 SAN DIEGO, Dec. 09, 2020 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 16,666,667 shares of common stock of the Company, at a price to the public of 4.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 14, 2020, subject to satisfaction of customary closing conditions. 